The lawyer’s team from STOICA & ASOCIAȚII – Dragoș Bogdan (Managing Partner) and Mihai Stănescu (Managing Associate) -, acting for a major global manufacturer of innovative medicines, won in a series of litigations the provisional ban on the sale of competing products by other major pharmaceutical companies, which violated the exclusive rights conferred by a patent.
The litigations concerned a very important medicine, having annual sales of over 4.5 billion euros. In the context of the termination of protection over the active substance of the drug in question, several generic drug companies tried to enter the Romanian market, ignoring the existence of a second-generation patent – which protected other characteristics of the drug than the active substance.
